Ibandronate - a new effective amonobhisphosphate in the treatment of postmenopausal osteoporosis

Osteoporosis is a civilization disease which represents a health, economic, and social challenge. Osteoporosis may result in fractures of which mainly vertebral and hip fractures lead to increased morbidity and mortality rates. The main goal of management is to prevent fractures, additional goals include maintaining or modifying bone mass amount and quality, reducing the clinical consequences of fractures and skeletal deformities, and preserving physical fitness. Poor adherence to treatment has been shown to be of major concern in the care of patients with osteoporosis. Adherence to treatment with oral bisphosphonates decreases dramatically during the course of the first year of treatment and it continues to decrease further. The result is inadequate reduction in bone turnover, lower increase of bone mineral density, and increased risk of fractures. Adherence to treatment may be improved by prolonging the dosage interval. Ibandronate (Bonviva) is a new effective aminobisphosphonate in the prevention and treatment of postmenopausal osteoporosis.

Keywords: osteoporosis, adherence to treatment, ibandronate